AU Patent

AU2009243422B2 — Combination of azelastine and steroids

Assigned to Cipla Ltd · Expires 2012-03-29 · 14y expired

What this patent protects

A pharmaceutical formulation which comprises azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and mometasone or a pharmaceutically acceptable ester thereof. 21316061 (GHMatters) 30/11/09

USPTO Abstract

A pharmaceutical formulation which comprises azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and mometasone or a pharmaceutically acceptable ester thereof. 21316061 (GHMatters) 30/11/09

Drugs covered by this patent

azelastine-hydrochloride (AZELASTINE HYDROCHLORIDE)

Patent Metadata

Patent number: AU2009243422B2
Jurisdiction: AU
Classification: —
Expires: 2012-03-29
Drug substance claim: No
Drug product claim: No
Assignee: Cipla Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.